for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZNCF.PK

Latest Trade

108.49USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

75.15

 - 

126.70

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
108.49
Open
--
Volume
--
3M AVG Volume
33.68
Today's High
--
Today's Low
--
52 Week High
126.70
52 Week Low
75.15
Shares Out (MIL)
1,312.29
Market Cap (MIL)
112,541.80
Forward P/E
27.79
Dividend (Yield %)
2.52

Next Event

Q3 2020 AstraZeneca PLC Earnings Release

Latest Developments

More

Samsung Biologics Says Co & AstraZeneca Forge Strategic Manufacturing Partnership For Global Supply

AstraZeneca Says Lynparza Recommended For EU Nod By CHMP

Merck & Co Inc Says Lynparza Improved Median Progression-Free Survival To Over 4.5 Years Vs 13.8 Months With Placebo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.27 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.6K
EPS (USD)

2017

4.280

2018

3.460

2019

3.500

2020(E)

3.935
Price To Earnings (TTM)
66.83
Price To Sales (TTM)
5.58
Price To Book (MRQ)
11.72
Price To Cash Flow (TTM)
24.59
Total Debt To Equity (MRQ)
161.37
LT Debt To Equity (MRQ)
127.60
Return on Investment (TTM)
4.83
Return on Equity (TTM)
3.36

Latest News

Latest News

Serum Institute to boost production of COVID-19 vaccine doses to 200 million

Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.

Serum Institute to boost production of COVID-19 vaccine doses to 200 million

Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.

FACTBOX-The race for a coronavirus vaccine

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...

Italian firm developing AstraZeneca's COVID-19 vaccine might go public -CEO

Italian biotech firm IRBM, which is cooperating with British drugmaker AstraZeneca <AZN.L> in developing a COVID-19 vaccine, could be listed on the stock exchange, its chief executive said on Monday.

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

AstraZeneca still waiting for FDA go-ahead to resume U.S. trial

AstraZeneca <AZN.L> is still waiting for the U.S. drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States almost three weeks after it was paused due to safety concerns.

UPDATE 2-UK shares drop as job support scaled back; AstraZeneca weighs

* New measures won't eliminate economic hit entirely - analyst

AstraZeneca not involved in planned COVID-19 human challenge trial

AstraZeneca said that it has no involvement in a planned clinical trial where volunteers would be given an experimental vaccine and then be deliberately infected with the new coronavirus, as reported by the Financial Times.

U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC

U.S. Health and Human Services Secretary Alex Azar said on Wednesday that the U.S. trial of AstraZeneca PLC's COVID-19 vaccine remains on hold while the U.S. Food and Drug Administration investigates a patient illness that shut down the global trial.

COVID-19 vaccine makers see EU shield against side-effect claims

Vaccine makers will be indemnified in Europe if their COVID-19 shots cause unexpected side-effects, an industry official said on Tuesday, urging European regulators to set up more predictable schemes to compensate possible victims.

FACTBOX-EU tries to catch-up after U.S., UK spend billions to secure coronavirus vaccines

(Adds ReiThera; updates Sanofi, AstraZeneca, Novavax, Johnson & Johnson) Sept 21 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. The European Union also signed its...

FACTBOX- The race for a coronavirus vaccine

(Updates Moderna, adds Beijing Wantai Biological Pharmacy, COVAXX, University Hospital Tuebingen, China's Institute of Biotechnology) Sept 21 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human...

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

AstraZeneca-Merck's Lynparza wins EU panel recommendation for cancer treatments

A European regulatory panel has recommended the approval of Lynparza, a blockbuster cancer treatment developed by AstraZeneca Plc and Merck & Co Inc, to treat two separate forms of cancer.

AstraZeneca says COVID-19 vaccine trial in U.S still on hold

AstraZeneca Plc <AZN.L> said on Saturday that its COVID-19 vaccine trial in the United States is still on hold.

AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain

AstraZeneca's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday.

Morocco orders COVID-19 vaccine as cases approach 100,000

Morocco on Friday signed a deal with Russia's R-Pharm to buy a COVID-19 vaccine produced under a licence from Britain’s AstraZeneca, the health ministry said, as its total number of cases approached 100,000.

AstraZeneca's trial illnesses may not be due to COVID-19 shot, Oxford University says

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.

Italy could have AstraZeneca COVID-19 shots by end November, IRBM biotech says

Italy could have its first shots of British drugmaker AstraZeneca's potential COVID-19 vaccine by the end of November, the managing director of IRBM told Reuters.

AstraZeneca's trial illnesses may not be due to COVID-19 shot - Oxford Univ

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted https://covid19vaccinetrial.co.uk/files...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up